{"count": 5, "results": [{"_id": "34879473", "pmid": 34879473, "pmcid": "PMC8747910", "title": "Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease", "journal": "Korean J Intern Med", "authors": ["Kim JW", "Choe JY", "Park SH"], "date": "2022-01-01T00:00:00Z", "doi": "10.3904/kjim.2021.363", "meta_date_publication": "2022 Jan", "meta_volume": "37", "meta_issue": "1", "meta_pages": "13-26", "score": 50263.035, "text_hl": "The efficacy of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ has been investigated in preclinical and clinical studies on @DISEASE_Arthritis_Rheumatoid @DISEASE_MESH:D001172 @@@rheumatoid arthritis@@@, @DISEASE_Osteoarthritis @DISEASE_MESH:D010003 @@@osteoarthritis@@@, @DISEASE_Lupus_Erythematosus_Systemic @DISEASE_MESH:D008180 @@@systemic lupus erythematosus@@@, @DISEASE_Sjogren's_Syndrome @DISEASE_MESH:D012859 @@@Sjogren's syndrome@@@, @<m>DISEASE_Scleroderma_Systemic</m> @DISEASE_MESH:D012595 @@@scleroderma@@@, @DISEASE_Spondylitis_Ankylosing @DISEASE_MESH:D013167 @@@ankylosing spondylitis@@@, and @DISEASE_Gout @DISEASE_MESH:D006073 @@@gout@@@. ", "citations": {"NLM": "Kim JW, Choe JY, Park SH. Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease Korean J Intern Med. 2022 Jan;37(1):13-26. PMID: 34879473", "BibTeX": "@article{34879473, title={Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease}, author={Kim JW and Choe JY and Park SH}, journal={Korean J Intern Med}, volume={37}, number={1}, pages={13-26}}"}}, {"_id": "35169250", "pmid": 35169250, "pmcid": "PMC8847622", "title": "Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis", "journal": "Sci Rep", "authors": ["Karatas A", "Oz B", "Celik C", "Akar ZA", "Akkoc RF", "Etem EO", "Dagli AF", "Koca SS"], "date": "2022-02-15T00:00:00Z", "doi": "10.1038/s41598-022-06581-1", "meta_date_publication": "2022 Feb 15", "meta_volume": "12", "meta_issue": "1", "meta_pages": "2553", "score": 50257.66, "text_hl": "@CHEMICAL_tofacitinib @CHEMICAL_MESH:C479163 @@@Tofacitinib@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ reduce the dermal thickness and @DISEASE_Fibrosis @DISEASE_MESH:D005355 @@@fibrosis@@@ in @SPECIES_10090 @@@mouse@@@ model of @<m>DISEASE_Scleroderma_Systemic</m> @DISEASE_MESH:D012595 @@@systemic sclerosis@@@", "citations": {"NLM": "Karatas A, Oz B, Celik C, Akar ZA, Akkoc RF, Etem EO, Dagli AF, Koca SS. Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis Sci Rep. 2022 Feb 15;12(1):2553. PMID: 35169250", "BibTeX": "@article{35169250, title={Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis}, author={Karatas A and Oz B and Celik C and Akar ZA and Akkoc RF and Etem EO and Dagli AF and Koca SS}, journal={Sci Rep}, volume={12}, number={1}, pages={2553}}"}}, {"_id": "33947424", "pmid": 33947424, "pmcid": "PMC8097822", "title": "Metformin ameliorates scleroderma via inhibiting Th17 cells and reducing mTOR-STAT3 signaling in skin fibroblasts", "journal": "J Transl Med", "authors": ["Moon J", "Lee SY", "Choi JW", "Lee AR", "Yoo JH", "Moon SJ", "Park SH", "Cho ML"], "date": "2021-05-04T00:00:00Z", "doi": "10.1186/s12967-021-02860-z", "meta_date_publication": "2021 May 4", "meta_volume": "19", "meta_issue": "1", "meta_pages": "192", "score": 50257.508, "text_hl": "Histological assessment demonstrated protective effects of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ against @<m>DISEASE_Scleroderma_Systemic</m> @DISEASE_MESH:D012595 @@@scleroderma@@@. ", "citations": {"NLM": "Moon J, Lee SY, Choi JW, Lee AR, Yoo JH, Moon SJ, Park SH, Cho ML. Metformin ameliorates scleroderma via inhibiting Th17 cells and reducing mTOR-STAT3 signaling in skin fibroblasts J Transl Med. 2021 May 4;19(1):192. PMID: 33947424", "BibTeX": "@article{33947424, title={Metformin ameliorates scleroderma via inhibiting Th17 cells and reducing mTOR-STAT3 signaling in skin fibroblasts}, author={Moon J and Lee SY and Choi JW and Lee AR and Yoo JH and Moon SJ and Park SH and Cho ML}, journal={J Transl Med}, volume={19}, number={1}, pages={192}}"}}, {"_id": "34154617", "pmid": 34154617, "pmcid": "PMC8218406", "title": "Correction to: Metformin ameliorates scleroderma via inhibiting Th17 cells and reducing mTOR-STAT3 signaling in skin fibroblasts", "journal": "J Transl Med", "authors": ["Moon J", "Lee SY", "Choi JW", "Lee AR", "Yoo JH", "Moon SJ", "Park SH", "Cho ML"], "date": "2021-06-21T00:00:00Z", "doi": "10.1186/s12967-021-02916-0", "meta_date_publication": "2021 Jun 21", "meta_volume": "19", "meta_issue": "1", "meta_pages": "266", "score": 50254.68, "text_hl": "Correction to: @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ ameliorates @<m>DISEASE_Scleroderma_Systemic</m> @DISEASE_MESH:D012595 @@@scleroderma@@@ via inhibiting Th17 cells and reducing @GENE_MTOR @GENE_2475 @@@mTOR@@@-@GENE_STAT3 @GENE_6774 @@@STAT3@@@ signaling in skin fibroblasts", "citations": {"NLM": "Moon J, Lee SY, Choi JW, Lee AR, Yoo JH, Moon SJ, Park SH, Cho ML. Correction to: Metformin ameliorates scleroderma via inhibiting Th17 cells and reducing mTOR-STAT3 signaling in skin fibroblasts J Transl Med. 2021 Jun 21;19(1):266. PMID: 34154617", "BibTeX": "@article{34154617, title={Correction to: Metformin ameliorates scleroderma via inhibiting Th17 cells and reducing mTOR-STAT3 signaling in skin fibroblasts}, author={Moon J and Lee SY and Choi JW and Lee AR and Yoo JH and Moon SJ and Park SH and Cho ML}, journal={J Transl Med}, volume={19}, number={1}, pages={266}}"}}, {"_id": "31344551", "pmid": 31344551, "title": "Metformin attenuates bleomycin-induced scleroderma by regulating the balance of Treg/Teff cells and reducing spleen germinal center formation.", "journal": "Mol Immunol", "authors": ["Wang Y", "Zhang S", "Liang Z", "Feng M", "Zhao X", "Qin K", "Gao C", "Li X", "Guo H", "Luo J"], "date": "2019-10-01T00:00:00Z", "doi": "10.1016/j.molimm.2019.07.002", "meta_date_publication": "2019 Oct", "meta_volume": "114", "meta_issue": "", "meta_pages": "72-80", "score": 50058.668, "text_hl": "These results suggest that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@MET@@@ may be a potential therapeutic for @<m>DISEASE_Scleroderma_Systemic</m> @DISEASE_MESH:D012595 @@@scleroderma@@@.", "citations": {"NLM": "Wang Y, Zhang S, Liang Z, Feng M, Zhao X, Qin K, Gao C, Li X, Guo H, Luo J. Metformin attenuates bleomycin-induced scleroderma by regulating the balance of Treg/Teff cells and reducing spleen germinal center formation. Mol Immunol. 2019 Oct;114():72-80. PMID: 31344551", "BibTeX": "@article{31344551, title={Metformin attenuates bleomycin-induced scleroderma by regulating the balance of Treg/Teff cells and reducing spleen germinal center formation.}, author={Wang Y and Zhang S and Liang Z and Feng M and Zhao X and Qin K and Gao C and Li X and Guo H and Luo J}, journal={Mol Immunol}, volume={114}, pages={72-80}}"}}]}